-
Je něco špatně v tomto záznamu ?
Pretreatment Serum Levels of Soluble Cytokeratin Fragments (Cyfra 21-1, TPS, MonoTotal) in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas
D. Kalfert, J. Ludvik, R. Kucera, O. Topolcan, P. Celakovsky, M. Pesta, I. Kholova, J. Plzak, M. Ludvikova,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2004 do Před 2 roky
Open Access Digital Library
od 2004-01-01
- MeSH
- antigeny nádorové krev MeSH
- dlaždicobuněčné karcinomy hlavy a krku krev diagnóza mortalita terapie MeSH
- keratin-19 krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- nádorové biomarkery * MeSH
- peptidy krev MeSH
- prognóza MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND/AIM: The aim of this study was to analyze the pretreatment cytokeratin serum levels in head and neck squamous cell carcinoma (HNSCC) by three assays in relation to selected clinicopathological characteristics in an effort to find diagnostic/prognostic biomarkers for HNSCC and determine the best assay. PATIENTS AND METHODS: In total, 46 patients with HNSCC with different subsite (oropharyngeal-21 cases, hypopharyngeal-4 and laryngeal-21) were included in this prospective study. MonoTotal, Cyfra 21-1, and TPS radioimmunoassay kits were used to analyze cytokeratin fragments serum levels. RESULTS: Statistically significant differences in serum levels of TPS and Cyfra 21-1 were found between low (stage I-II)- and high-stage (stage III-IV) tumors (p=0.0057; p=0.0138 respectively). Cyfra21-1 assay showed significant differences between tumors of different sites with prominent elevation being found in oropharyngeal carcinomas and between patients with p16 positive and p16 negative HNSCC (p=0.0242), being elevated in p16 positive tumors. CONCLUSION: The present study is the first to compare cytokeratin serum levels between various subgroups of HNSCC using three different assays. Cyfra 21-1 seems to be the most useful for clinical practice. The relation between elevated Cyfra 21-1 serum levels and p16 expression requires further investigation.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034418
- 003
- CZ-PrNML
- 005
- 20191010110526.0
- 007
- ta
- 008
- 191007s2019 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.13713 $2 doi
- 035 __
- $a (PubMed)31519630
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Kalfert, David $u Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Motol, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Pretreatment Serum Levels of Soluble Cytokeratin Fragments (Cyfra 21-1, TPS, MonoTotal) in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas / $c D. Kalfert, J. Ludvik, R. Kucera, O. Topolcan, P. Celakovsky, M. Pesta, I. Kholova, J. Plzak, M. Ludvikova,
- 520 9_
- $a BACKGROUND/AIM: The aim of this study was to analyze the pretreatment cytokeratin serum levels in head and neck squamous cell carcinoma (HNSCC) by three assays in relation to selected clinicopathological characteristics in an effort to find diagnostic/prognostic biomarkers for HNSCC and determine the best assay. PATIENTS AND METHODS: In total, 46 patients with HNSCC with different subsite (oropharyngeal-21 cases, hypopharyngeal-4 and laryngeal-21) were included in this prospective study. MonoTotal, Cyfra 21-1, and TPS radioimmunoassay kits were used to analyze cytokeratin fragments serum levels. RESULTS: Statistically significant differences in serum levels of TPS and Cyfra 21-1 were found between low (stage I-II)- and high-stage (stage III-IV) tumors (p=0.0057; p=0.0138 respectively). Cyfra21-1 assay showed significant differences between tumors of different sites with prominent elevation being found in oropharyngeal carcinomas and between patients with p16 positive and p16 negative HNSCC (p=0.0242), being elevated in p16 positive tumors. CONCLUSION: The present study is the first to compare cytokeratin serum levels between various subgroups of HNSCC using three different assays. Cyfra 21-1 seems to be the most useful for clinical practice. The relation between elevated Cyfra 21-1 serum levels and p16 expression requires further investigation.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a antigeny nádorové $x krev $7 D000951
- 650 12
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a keratin-19 $x krev $7 D053539
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a peptidy $x krev $7 D010455
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a dlaždicobuněčné karcinomy hlavy a krku $x krev $x diagnóza $x mortalita $x terapie $7 D000077195
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ludvik, Jaroslav $u Departments of Imaging Methods, University Hospital Pilsen, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic ludvikj@fnplzen.cz.
- 700 1_
- $a Kucera, Radek $u Department of Immunochemistry, University Hospital Pilsen, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
- 700 1_
- $a Topolcan, Ondrej $u Department of Immunochemistry, University Hospital Pilsen, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
- 700 1_
- $a Celakovsky, Petr $u Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Hradec Kralove, Faculty of Medicine in Hradec Kralove, Charles University, Prague, Czech Republic.
- 700 1_
- $a Pesta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
- 700 1_
- $a Kholova, Ivana $u Pathology, Fimlab Laboratories and Department of Pathology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- 700 1_
- $a Plzak, Jan $u Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Motol, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Ludvikova, Marie $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 39, č. 9 (2019), s. 5171-5177
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31519630 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191010110945 $b ABA008
- 999 __
- $a ok $b bmc $g 1451078 $s 1072968
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 39 $c 9 $d 5171-5177 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20191007
